Cargando…

Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer

OBJECTIVE: To describe patient profiles and clinical outcomes associated with first-line endocrine monotherapy (ET) and chemotherapy (CT) for postmenopausal HR+/HER2− metastatic breast cancer (mBC) patients. METHODS: This is a retrospective chart review of 139 postmenopausal HR+/HER2− mBC patients i...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yan, Hao, Yanni, Macalalad, Alexander R., Lin, Peggy L., Signorovitch, James E., Wu, Eric Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560455/
https://www.ncbi.nlm.nih.gov/pubmed/26380551
http://dx.doi.org/10.4137/BCBCR.S30771
_version_ 1782388925446225920
author Song, Yan
Hao, Yanni
Macalalad, Alexander R.
Lin, Peggy L.
Signorovitch, James E.
Wu, Eric Q.
author_facet Song, Yan
Hao, Yanni
Macalalad, Alexander R.
Lin, Peggy L.
Signorovitch, James E.
Wu, Eric Q.
author_sort Song, Yan
collection PubMed
description OBJECTIVE: To describe patient profiles and clinical outcomes associated with first-line endocrine monotherapy (ET) and chemotherapy (CT) for postmenopausal HR+/HER2− metastatic breast cancer (mBC) patients. METHODS: This is a retrospective chart review of 139 postmenopausal HR+/HER2− mBC patients initiating first-line ET monotherapy or CT. Overall survival (OS) was described using Kaplan–Meier curves. Exploratory comparative proportional hazards regression was conducted. RESULTS: Patients on first-line CT had significantly more frequent liver metastases than patients on first-line ET monotherapy at baseline. The median OS was 35.5 months [95% confidence interval (CI), 22.7–41.2 months] for patients on first-line ET monotherapy and 22.2 months (95% CI, 13.6–25.9 months) for those on first-line CT (P = 0.021). Adjusting for baseline characteristics, the OS between first-line ET monotherapy and CT was not significantly different. CONCLUSIONS: Patients who were prescribed CT as first-line treatment had evidence of more advanced disease at baseline and shorter OS than those who received ET monotherapy as first-line treatment, suggesting a need for additional safe and effective treatment options for these patients.
format Online
Article
Text
id pubmed-4560455
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-45604552015-09-17 Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer Song, Yan Hao, Yanni Macalalad, Alexander R. Lin, Peggy L. Signorovitch, James E. Wu, Eric Q. Breast Cancer (Auckl) Original Research OBJECTIVE: To describe patient profiles and clinical outcomes associated with first-line endocrine monotherapy (ET) and chemotherapy (CT) for postmenopausal HR+/HER2− metastatic breast cancer (mBC) patients. METHODS: This is a retrospective chart review of 139 postmenopausal HR+/HER2− mBC patients initiating first-line ET monotherapy or CT. Overall survival (OS) was described using Kaplan–Meier curves. Exploratory comparative proportional hazards regression was conducted. RESULTS: Patients on first-line CT had significantly more frequent liver metastases than patients on first-line ET monotherapy at baseline. The median OS was 35.5 months [95% confidence interval (CI), 22.7–41.2 months] for patients on first-line ET monotherapy and 22.2 months (95% CI, 13.6–25.9 months) for those on first-line CT (P = 0.021). Adjusting for baseline characteristics, the OS between first-line ET monotherapy and CT was not significantly different. CONCLUSIONS: Patients who were prescribed CT as first-line treatment had evidence of more advanced disease at baseline and shorter OS than those who received ET monotherapy as first-line treatment, suggesting a need for additional safe and effective treatment options for these patients. Libertas Academica 2015-09-03 /pmc/articles/PMC4560455/ /pubmed/26380551 http://dx.doi.org/10.4137/BCBCR.S30771 Text en © 2015 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article published under the Creative Commons CC-BY-NC 3.0 license.
spellingShingle Original Research
Song, Yan
Hao, Yanni
Macalalad, Alexander R.
Lin, Peggy L.
Signorovitch, James E.
Wu, Eric Q.
Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
title Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
title_full Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
title_fullStr Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
title_full_unstemmed Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
title_short Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
title_sort clinical outcomes with first-line endocrine therapy or chemotherapy in postmenopausal hr+/her2− metastatic breast cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560455/
https://www.ncbi.nlm.nih.gov/pubmed/26380551
http://dx.doi.org/10.4137/BCBCR.S30771
work_keys_str_mv AT songyan clinicaloutcomeswithfirstlineendocrinetherapyorchemotherapyinpostmenopausalhrher2metastaticbreastcancer
AT haoyanni clinicaloutcomeswithfirstlineendocrinetherapyorchemotherapyinpostmenopausalhrher2metastaticbreastcancer
AT macalaladalexanderr clinicaloutcomeswithfirstlineendocrinetherapyorchemotherapyinpostmenopausalhrher2metastaticbreastcancer
AT linpeggyl clinicaloutcomeswithfirstlineendocrinetherapyorchemotherapyinpostmenopausalhrher2metastaticbreastcancer
AT signorovitchjamese clinicaloutcomeswithfirstlineendocrinetherapyorchemotherapyinpostmenopausalhrher2metastaticbreastcancer
AT wuericq clinicaloutcomeswithfirstlineendocrinetherapyorchemotherapyinpostmenopausalhrher2metastaticbreastcancer